Skip to Content
CancersCancers
  • Article
  • Open Access

20 November 2026

13 Pages

Prospective Comparison of Two Robotic Platforms for the Performance of Radical Prostatectomy: Versius vs. DaVinci

,
,
,
and
Urology Unit of Hospital Universitario Ramón y Cajal, University of Alcalá, 28034 Madrid, Spain
*
Author to whom correspondence should be addressed.
Cancers2026, 18(22), 3710;https://doi.org/10.3390/cancers18223710 
(registering DOI)
This article belongs to the Section Methods and Technologies Development

Simple Summary

Robot-assisted radical prostatectomy is widely used to treat localized prostate cancer. Although the DaVinci robotic system has been used for many years, newer platforms, such as Versius, are becoming available. We compared the outcomes of 278 patients undergoing radical prostatectomy using these two systems. Both platforms showed similar short-term surgical safety and cancer-related outcomes. However, differences were observed in nerve-sparing procedures, lymph node removal, and early urinary continence recovery. These findings suggest that Versius may be a feasible alternative to the established DaVinci system. Further studies with longer follow-up are needed to determine whether these differences persist and whether they affect long-term cancer control and quality of life.

Abstract

Background/Objectives: To compare the perioperative, oncological, and functional outcomes of the Versius® and DaVinci® systems as used for performing robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer. Methods: Prospective observational comparative study of 278 patients subjected to RARP between March 2023 and September 2025. 169 procedures were performed with the Versius® system and 109 with the DaVinci® system. An analysis was performed of a series of demographic, perioperative, pathological, and functional variables. Quantitative variables were compared using either Student’s t or the Mann–Whitney Test, while categorical variables were analyzed with the chi-squared test or Fisher’s Exact Test. Results: Both groups exhibited comparable baseline characteristics. No significant differences were observed in lymphadenectomy rates, perioperative complications, transfusion requirements, length of hospital stay, or postoperative PSA levels. The DaVinci® group showed higher rates of neurovascular bundle preservation (48.6% vs. 17.4%; p < 0.001) and greater lymph node yield (14.27 vs. 10.78 nodes; p < 0.001). Pathological lymph node involvement (pN1) was more frequent in the DaVinci® group (20.4% vs. 5.1%; p = 0.019). No significant differences were observed in positive surgical margins, pathological T stage, or specimen ISUP grade. Urinary incontinence was more frequent in the Versius® group at 3 and 6 months (p = 0.003 and p = 0.034, respectively), with no statistically significant difference at 12 months. Conclusions: Both Versius® and DaVinci® were shown to be safe and effective platforms for the performance of RARP, with comparable short-term perioperative and oncological outcomes.

1. Introduction

Prostate cancer is the second most diagnosed cancer worldwide among men, the first in incidence in Europe and the third cause of cancer-specific death in men [1]. Radical prostatectomy (RP) remains one of the standard treatment options for patients with localized prostate cancer, as recommended by current international clinical practice guidelines [2,3,4,5]. It was not until the 1990’s that the first laparoscopic radical prostatectomy (LRP) was carried out, paving the way for a decrease in the occurrence of postoperative complications and a more successful recovery of patients, albeit at the expense of a steep learning curve [4,5].
Nowadays, however, thanks to the expansion of robotic surgery, robot-assisted radical prostatectomy (RARP) has become the standard of care for the surgical treatment of PC in specialized centers [6,7,8,9].
The first-ever RARP was completed in the year 2000 by Abbou et al [5]. This novel technique, which was subsequently popularized by Menon et al. [5], offers such advantages as three-dimensional visualization, the use of articulated instruments, and improved surgeon ergonomics. Some further advantages associated with RARP include a reduction in intraoperative blood loss, as well as more effective and faster patient recovery, which typically results in a shorter hospital stay [9,10,11].
In the last two decades, the field of RARP was dominated by the DaVinci® system (Intuitive Surgical®). Nevertheless, the last few years have seen the development of new robotic platforms, the most noteworthy of which are the Versius® (CMR Surgical®) and the Hugo™RAS (Medtronic®) modular robots [11,12,13,14].
The DaVinci® X/Xi consists of three separate components: a surgeon console, a patient-side cart, and a vision cart. The surgeon operates from a closed console providing three-dimensional high-definition visualization and controls the robotic instruments through hand manipulators and foot pedals. In the DaVinci® Xi configuration, four robotic arms are mounted on a single patient-side cart, and the system employs articulated 8-mm instruments with seven degrees of freedom [15].
On the other hand, Versius® is a modular robotic system that comprises an open console and up to four robotic arms with articulated instruments. The open console, with its three-dimensional screen, allows the lead surgeon to perform the operation in a standing or seated position, according to their personal preference, and facilitates direct communication with the surgical team. Each robotic arm is assembled onto a bedside unit capable of holding 5 mm articulated instruments such as needle-holders, scissors or graspers. Each is capable of up to 11 ranges of movement and 360º of wrist rotation [12,13,16,17].
The robotic arms can be positioned freely around the patient and adjusted to the latter’s anatomical characteristics, which makes the Versius® system highly versatile. It is, however, essential to place the arms in the correct position to prevent clashes between the robotic instruments and excessively steep intra-abdominal angles [12,13,16,17].
The Versius® system also incorporates telemetry data (console start/stop times, movement patterns, locking times, robotic arm release times, alarms and the number and type of instruments used), which provide information on surgical performance and may allow for improvements to the surgical technique. Moreover, the surgeon can record the procedure for subsequent review [16,18].
The data available on the advantages of the Versius® system over other well-established systems such as DaVinci® are inconclusive, which presents a major dilemma for urologists. The primary aim of the present study was to compare the clinical, oncological, and functional outcomes of the Versius® vs. the DaVinci® system in patients with localized prostate cancer (LPC) undergoing RARP at the Ramón y Cajal Hospital, where both technologies have been used interchangeably by a group of RARP-trained surgeons since 2023. The secondary objectives were to compare perioperative outcomes, including intraoperative and postoperative complications, and to assess the safety profiles of both robotic systems.

2. Materials and Methods

2.1. Study Design

This is a non-randomized, prospective observational comparative study on 278 patients subjected to RARP in our hospital between March 2023 and September 2025. The main goal was to evaluate and compare the surgical, oncological, and functional outcomes of two different robotic platforms: the DaVinci® system (Intuitive Surgical, Sunnyvale, CA, USA) and the Versius® system (CMR Surgical, Cambridge, UK).
This study was carried out in accordance with the Helsinki Declaration on the Ethical Principles for Medical Research involving Human Subjects [19] and was approved by the Ethics Committee in our hospital on 2 October 2025 (protocol CEIm code: 257/25).

2.2. Patient Recruitment and Variables Analyzed

Data were prospectively collected between March 2023 and September 2025 from consecutive patients scheduled to undergo RARP at our institution. Patients were eligible for inclusion if they had a histologically confirmed diagnosis of localized prostate cancer based on prostate biopsy and had provided written informed consent for surgery. Preoperative staging was performed to exclude metastatic disease, with computed tomography (CT) and bone scintigraphy or prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in patients classified as high-risk according to the European Association of Urology (EAU) guidelines [20]. A total of 281 patients met the eligibility criteria.
Patients in whom RARP was initially planned but could not be completed robotically, requiring conversion to laparoscopic or open surgery due to technical difficulties or anesthetic complications, were excluded from the comparative analysis. The study population therefore comprised patients who underwent completed RARP using either the Versius® or DaVinci® robotic surgical system.
The patients’ demographic and clinical variables (age, height, weight, and body mass index (BMI)) were recorded at the beginning of the study. Other analyzed variables included: prostate volume as measured by magnetic resonance imaging (MRI); preoperative prostate specific antigen (PSA) levels (normal level: 0–4.5 ng/mL); PI-RADS score of the suspicious lesion detected on MRI; preoperative ISUP grade; type of robotic system used; degree of neurovascular bundle preservation; performance or otherwise of an extended pelvic lymph node dissection; number and type of intra- and postoperative complications during the first two months postoperative according to the Clavien–Dindo classification; pre- and postoperative hemoglobin difference; need for a blood transfusion; drainage time; length of hospital stay; ISUP grade of the specimen; tumor grade; N-stage; number of lymph nodes obtained during the dissection; degree of positivity of the dissection; positive surgical margins (defined as the presence of tumor cells in direct contact with the inked surgical resection margin, regardless of the extent of involvement); perineural invasion; tumor volume (%); prostate volume; postoperative PSA levels, length of vesical catheterization; visits to the emergency room; rate of readmissions; and incontinence at 3, 6 and 12 months postoperative (defined as the use of one or more incontinence pads a day).

2.3. Interventions

All the procedures were carried out by the team of surgeons in our department, made up of four surgeons with vast experience in laparoscopic and/or robotic surgery. The choice of robotic system depended purely on operating room availability, without application of any randomization criteria or taking into consideration the surgeons’ preference.
Four robotic arms were used with both the DaVinci® and the Versius® systems, with up to two supplementary ports being subsequently added by an assistant at the surgeon’s discretion.
Every operation consisted of a transperitoneal or extraperitoneal RP carried out according to the steps laid down in guidelines such as those of the EAU, i.e., Retzius space dissection after deroofing of the bladder (only for the transperitoneal approach); bladder neck dissection; vas deferens and seminal vesicle excision; Denonvilliers fascia dissection; dissection of the lateral and anterior aspects of the prostate; prostatectomy; vesicourethral anastomosis with a continuous V-loc suture on a permanent 22 Ch vesical catheter; and aspiration drain placement.
In cases where the risk of lymph node involvement according to the Briganti 2018 nomogram was higher than 7% [21], an extended pelvic lymph node dissection was performed, including dissection of lymph nodes between the external iliac vessels laterally up to the lateral aspect of the bladder medially, and from the iliac bifurcation cranially to Cloquet’s node or the circumflex vein caudally. The dissection continued into the deeper layers, reaching the obturator nerve.
Preservation or otherwise of the neurovascular bundles was decided on a case-by-case basis depending on the tumor’s histological characteristics and the patients’ anatomical characteristics, in accordance with the recommendations of the EAU guidelines [20].

2.4. Statistical Analysis

The data were analyzed using IBM SPSS Statistics software, v 29.0. Quantitative variables are expressed as mean ± standard deviation (SD), while qualitative variables are expressed as frequencies and percentages. Between-group comparisons were made using Student’s t test or the Mann–Whitney test for quantitative variables and the chi-squared test or Fisher’s Exact Test for categorical variables. Statistical significance was set at a p-value < 0.05.
To account for potential confounding factors in postoperative urinary continence outcomes, multivariable binary logistic regression analyses were performed at 3, 6, and 12 months. Urinary incontinence was defined as the use of one or more incontinence pads per day. The robotic platform was included as the main explanatory variable, with adjustment for patient age and neurovascular bundle preservation. Results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Patients without an available continence assessment at the corresponding follow-up time point or with missing covariate data were excluded from that specific model.

3. Results

Of the 281 eligible patients, three patients initially scheduled for RARP using the Versius® system required conversion to laparoscopic surgery due to technical difficulties in two cases and the patient’s intolerance of the Trendelenburg position and of pneumoperitoneum in the third case.
Consequently, 278 patients who underwent completed RARP at Ramón y Cajal University Hospital (Madrid, Spain) between March 2023 and September 2025 were included in the comparative analysis. Following histological confirmation of prostate adenocarcinoma by prostate biopsy, patients were informed about the available therapeutic options by urologists specializing in prostate cancer. Of the 278 patients included in the comparative analysis, 169 underwent RARP using the Versius® system (60.79%), while 109 underwent RARP using the DaVinci® system (39.21%).

3.1. Baseline Characteristics

A total of 278 cases of LPC subjected to RARP were included in the study; 109 (39.21%) were operated with the DaVinci® system and 169 (60.79%) with the Versius® system. Table 1 includes the patients’ baseline characteristics and the data obtained from the patients’ MRI evaluation and diagnostic biopsy. All these data were comparable.
Table 1. Baseline characteristics of patients undergoing a robot-assisted radical prostatectomy using the two systems under analysis.

3.2. Intra- and Post-Operative Data

Table 2 contains the patients’ intra- and post-operative data.
Table 2. Intra- and postoperative results of robot-assisted radical prostatectomy using the two systems under analysis.
No statistically significant differences were found between the two groups with respect to the percentage of lymph node dissections performed (34.9% with Versius® vs. 45% with DaVinci®; p = 0.093). Nonetheless, a strikingly higher proportion of neurovascular bundle preservation was observed among patients operated using the DaVinci® system (17.4% for Versius® vs. 48.6% for DaVinci®, p < 0.001).
Use of the DaVinci® system (109 procedures) resulted in only one intraoperative complication, an iatrogenic bladder perforation that was resolved in situ by placement of a resorbable suture. As far as Versius® was concerned, the only complication was related to the need to temporarily interrupt an operation due to the patient’s tolerance of pneumoperitoneum.
The two robot-assisted systems were also comparable with regard to postoperative complications (Clavien–Dindo > 2). The only death occurred following a DaVinci®-assisted RARP, as a result of abdominal sepsis caused by a bowel perforation.
Similarly, no statistically significant differences were found with respect to the need for postoperative blood transfusion, length of drainage, or length of hospital stay.

3.3. Pathological Analysis

Table 3 presents the subjects’ pathological results following RARP. No statistically significant differences were observed between the groups with respect to ISUP grade or pT stage.
Table 3. Pathological analysis of the specimen retrieved during robot-assisted radical prostatectomy using the two systems under analysis.
Pelvic lymph node dissection was performed in 59 of 169 patients (34.9%) in the Versius® group and 49 of 109 patients (45.0%) in the DaVinci® group, with no statistically significant difference (p = 0.093). Among patients undergoing lymphadenectomy, lymph node metastases (pN1) were identified in 3 patients (5.1%) in the Versius® group and 10 patients (20.4%) in the DaVinci® group, representing a statistically significant difference (p = 0.019). A total of 636 lymph nodes were retrieved in the Versius® group and 699 in the DaVinci® group, with a mean lymph node yield of 10.78 ± 4.03 and 14.27 ± 5.88 nodes, respectively (p < 0.001). Among pN1 patients, the mean number of positive lymph nodes was 1.00 ± 0.00 in the Versius® group and 1.70 ± 1.89 in the DaVinci® group, with a median of 1 (IQR: 1–1) in both groups.
Findings with respect to margin positivity, perineural invasion, tumor cell percentage in the specimen, and prostate volume were comparable.

3.4. Postoperative Follow-Up Data

A summary of postoperative follow-up data is provided in Table 4. Median PSA levels at two months from the procedure were similar, as were the number of RARP-related visits to the emergency room and the rate of readmissions in both groups. The rate of urinary incontinence was significantly higher in the Versius® group at 3- and 6-month follow-up (p = 0.003 and p = 0.034, respectively). Although incontinence at 12 months was more persistent in patients in the Versius® group, the difference was not statistically significant (p = 0.063). The decreasing number of available assessments over time was attributed to patients not yet having reached the corresponding follow-up visits at the time of data analysis, rather than loss to follow-up.
Table 4. Follow-up results of robot-assisted radical prostatectomies performed using the two systems under analysis.
The results for multivariable logistic regression are provided in Table 5. In multivariable logistic regression analysis adjusted for age and neurovascular bundle preservation, the Versius® platform remained associated with higher odds of urinary incontinence at 3 months compared with DaVinci® (adjusted OR 1.99, 95% CI 1.14–3.49; p = 0.016). At 6 months, the association was attenuated and was no longer statistically significant (adjusted OR 1.59, 95% CI 0.79–3.23; p = 0.195). Similarly, no statistically significant association was observed at 12 months (adjusted OR 1.59, 95% CI 0.46–5.53; p = 0.469), although the limited number of events and available follow-up assessments reduced the precision of this estimate.
Table 5. Unadjusted and adjusted logistic regression analyses of urinary incontinence following robot-assisted radical prostatectomy.

4. Discussion

RP techniques have evolved significantly in the last few decades. The first-ever LRP was conducted in 1992 in the United States. Subsequently, the procedure was exported to Europe in the aftermath of Guillonneau et. al.’s 1999 article, which reported excellent oncological and functional results using a minimally invasive approach [22]. With the introduction of the DaVinci® robot in 2000, robotic surgery came to be increasingly utilized in all kinds of urologic procedures, including RP. Indeed, RARP has become the standard treatment for LPC in high-volume centers [12,23].
Unlike the DaVinci® system, the Hugo RAS® and Versius® modular robots are made up of four independent arms, which must be positioned at the right angle and the right distance from the surgical field in order to prevent instrument clashes during the procedure [24]. Versius® incorporates an ergonomic open console that allows surgeons to perform the operation in a seated or standing position while they communicate with the other members of the surgical team in real time [12,13,16].
Each one of these new systems is provided with specific features that may or may not make it superior to the rest. For that reason, the expansion of new robotic platforms has prompted the need to perform comparative evaluations of their oncological and functional performance. Our hospital has been equipped with both the Versius® and the DaVinci® systems since 2023.
The main purpose of this study was to carry out a comparative analysis of the oncological and functional outcomes observed in patients subjected to a RARP using both robotic platforms. All the procedures were performed by the same team of urologists in accordance with previously established protocols. Patients were not randomized; the choice of one robot over the other was based exclusively on operating room availability in the urology department.
No statistically significant differences were found in the baseline characteristics of our patients, including age, BMI, preoperative PSA levels, prostate size, or PI-RADS score of the lesions observed on MRI. Similarly, the prostate biopsies providing confirmation of a diagnosis of prostate cancer were found to have a similar ISUP grade in both groups.
Regarding the procedure itself, preservation of neurovascular bundles was found to be significantly higher with the DaVinci® system. Although no statistically significant difference was observed in the proportion of patients undergoing pelvic lymph node dissection, lymph node yield was higher in the DaVinci® group. These results could be attributable to the fact that urologists in our hospital had already accumulated some experience with the use of the DaVinci® system. However, differences in surgical decision-making, patient characteristics, and the extent of lymphadenectomy may also have contributed to these results. Therefore, the observed differences should not be interpreted as evidence of intrinsic superiority of either robotic system.
In their own comparison of the effectiveness of the DaVinci® and the Versius® systems for the performance of RARP, Dibitetto et al. similarly reported differences favoring the DaVinci®. Although the authors do not specify the number of lymph nodes resected, they did find significant differences in the number of completed lymph node dissections and in the preservation of neurovascular bundles. In their case, the lead surgeon had started out in the field of robotic surgery with the Versius® system [8].
Only one intraoperative complication occurred in each group. Moreover, three cases that had to be converted to laparoscopic or open surgery were excluded from the analysis. The failures were primarily related to the robotic system’s software. In one case, a malfunction involving the braking mechanism of one of the robotic arms was identified at the beginning of the procedure. The third cause of conversion was due to the patient’s intolerance of pneumoperitoneum and the Trendelenburg position.
Importantly, none of these incidents compromised patient safety, as the robotic system’s built-in safety mechanisms and alert systems allowed the surgical team to identify the malfunctions and respond appropriately. Furthermore, all three conversions occurred during the initial months of our experience with the Versius® platform. The technical issues were subsequently addressed, and no similar incidents have occurred since then at our institution.
In a description of their initial experience with Versius®-assisted RARP, Polom et al. reported only one conversion to open surgery (0.58%), motivated by an inflammation caused by administration of BCG immunotherapy prior to the operation [25].
The low conversion rates associated with robot-assisted surgery have been documented in the literature. In a systematic review, Reitano et al. included numerous series not only of robot-assisted radical prostatectomies, but also of other urologic procedures such as adrenalectomy, nephrectomy, or robot-assisted nephroureterectomy with negligible conversion rates to laparoscopic or open surgery [26].
No statistically significant difference in postoperative complication rates was observed between groups (4% Versius® vs. 8% DaVinci®, p = 0.15; for Clavien–Dindo > 2 complications). Data are also comparable with respect to length of drainage and hospitalization, blood transfusion requirements, number of visits to the emergency room, or the rate of readmissions. However, these findings should not be interpreted as demonstrating equivalent safety profiles, as the observational design and sample size may limit the ability to detect clinically relevant differences.
According to our protocols, removal of the catheter is indicated at around two weeks from the operation, regardless of the type of robot used. Surprisingly, other authors such as Polom et al. and Abdelhakim et al. advocate for earlier catheter removal (a median of 7.9 days and 7 days, respectively) [7,25].
As far as oncological outcomes are concerned, no statistically significant differences were observed with respect to pT staging, surgical margin positivity, or perineural invasion. Nevertheless, the proportion of positive surgical margins was numerically higher in the Versius® group (40.7% vs. 29.4%; p = 0.055), a difference that may be clinically relevant despite not reaching statistical significance. In their series of 60 RARPs with Versius®, Meneghetti et al. reported a surgical margin positivity in 35% of their cases (similar to our 40.7%). In their opinion, and in line with the literature, this is due to a high proportion of extraprostatic disease in their cohort [27,28].
A higher lymph node yield and a greater proportion of pN1 cases were observed in the DaVinci® group, consistent with some of the findings reported by Dibitetto et al. [8]. However, these differences should be interpreted cautiously, as they may reflect variations in the extent of lymphadenectomy, patient selection, or underlying tumor characteristics rather than an intrinsic advantage of the robotic platform. A review of the literature revealed other case series of Versius®-assisted RARP with heterogeneous pN1 disease rates: 0% in De María et al. and 14.4% in Abdelhakim et al. vs. 5.1% in our series [13,29].
As far as functional status is concerned, significant differences were observed in terms of urinary continence, with patients in the Versius® group demonstrating progressive functional improvement. The Versius®-assisted RARP results reported by De María et al., Polom et al., and Abdelhakim et al. are consistent with our own, reflecting a progressive recovery of urinary continence over time [13,25,29]. Nevertheless, these findings should be interpreted cautiously, particularly given the substantial difference in neurovascular bundle preservation between groups and the decreasing number of patients with available follow-up assessments.
Additional multivariable analyses adjusting for patient age and neurovascular bundle preservation showed that the association between the Versius® platform and higher urinary incontinence rates persisted at 3 months. However, this association was attenuated and was no longer statistically significant at 6 and 12 months. These findings suggest that the observed differences in continence recovery may be influenced by multiple factors beyond the robotic platform itself. Nevertheless, residual confounding cannot be excluded, particularly given the lack of adjustment for surgical approach, tumor risk, surgeon-specific experience, and case sequence. The 12-month results should also be interpreted cautiously because of the limited number of available assessments and incontinence events.
As mentioned above, Versius® is currently by no means the only competitor to DaVinci®. Other, increasingly popular modular robotic platforms such as HugoRAS can be used to perform RARP. The literature presents studies comparing the effectiveness of RARP using the HugoRAS vs. the DaVinci® system, such as those published by Brime Menendez et al., Gandi et al., or Balestrazzi et al. Their findings are in line with ours, with no significant differences observed in the oncological performance of these robotic platforms [11,30,31].
One of the main limitations of this study is the relatively short follow-up period, as approximately half of the patients had not yet reached the 12-month assessment at the time of analysis. This resulted in a progressively smaller sample size for urinary continence evaluation, particularly at 12 months, potentially reducing statistical power and limiting the interpretation of long-term functional outcomes. Nevertheless, the missing assessments were attributed to insufficient elapsed follow-up time rather than patient loss to follow-up. Indeed, correct evaluation of oncological and functional outcomes following RARP would require a more protracted follow-up period. Another important limitation is related to the study’s prospective non-randomized design, which is aggravated by the fact that the post-surgical collection of data could result in a selection bias, and the surgical results could be influenced by the experience of each individual surgeon. Furthermore, the absence of statistically significant differences in several outcomes should not be interpreted as evidence of equivalence or non-inferiority between the two robotic platforms. The study was not specifically designed or powered to establish equivalence, and no predefined equivalence margins were established.
On the other hand, this study also has its strengths. As our hospital was the first one in Spain to acquire both the Versius® and the DaVinci® robots, we were able to conduct an analysis which, to the best of our knowledge, is one of the first ones to ever compare both systems. The study also includes the largest Versius® cohort recruited so far. Our goal was to lay the foundations for future research and encourage other groups to publish their results on the subject. For our part, we shall remain committed to closely monitoring our patients and reevaluating our results over a longer follow-up period.

5. Conclusions

In sum, this prospective observational study makes a significant contribution to the state of the art by comparing the results of the Versius® and the DaVinci® systems in patients undergoing RARP. The perioperative and short-term postoperative results obtained demonstrated the effectiveness and safety of both systems. However, the DaVinci® group showed higher rates of neurovascular bundle preservation and greater lymph node yield, as well as lower urinary incontinence rates at 3 and 6 months. A higher proportion of pN1 cases was also observed in the DaVinci® group, although this finding should not be interpreted as evidence of superior surgical performance.
Our findings suggest that Versius® may represent a feasible alternative for RARP in appropriately selected patients. Nevertheless, the observational design, potential confounding factors, and limited follow-up preclude definitive conclusions regarding equivalence, comparative safety, or oncological effectiveness.
The continuing expansion of robotic surgery will make it necessary to intensify our research efforts, including the performance of more robust studies with longer follow-up periods, which may help elucidate the implications of the results obtained.

Author Contributions

Conceptualization, S.G.F. and S.G.B.; methodology, S.G.F. and S.G.B.; investigation, S.G.F. and G.M.S.; resources, S.G.B., G.M.S. and G.F.C.; data curation, S.G.F. and G.M.S.; formal analysis, S.G.B.; project administration, F.J.B.R.; writing—original draft preparation, S.G.F.; writing—review and editing, S.G.B., G.M.S., G.F.C. and F.J.B.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the Research Ethics Committee of Hospital Universitario Ramón y Cajal (the approval date is 2 October 2025, under protocol CEIm code 257/25).

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request. The dataset has been fully de-identified to ensure patient confidentiality.

Acknowledgments

During the preparation of this manuscript, the authors used ChatGPT (OpenAI; GPT-5.6 Sol) for English-language editing, refinement of scientific wording, and adaptation to journal-specific formatting and reporting requirements. The authors reviewed and edited all AI-assisted content and take full responsibility for the final manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript
LPCLocalized prostate cancer
PRRadical prostatectomy
RARPRobot-assisted radical prostatectomy
BMIBody mass index
CMRCambridge Medical Robotics
MRIMagnetic resonance imaging
PSAProstate-specific antigen
LRPLaparoscopic radical prostatectomy

References

  1. Lantz, A.; Bock, D.; Akre, O.; Angenete, E.; Bjartell, A.; Carlsson, S.; Koss Modig, K.; Nyberg, M.; Stinesen Kollberg, K.; Steineck, G.; et al. Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year follow-up. Eur. Urol. 2021, 80, 650–660. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Tang, K.; Jiang, K.; Chen, H.; Chen, Z.; Xu, H.; Ye, Z. Robotic vs. retropubic radical prostatectomy in prostate cancer: A systematic review and a meta-analysis update. Oncotarget 2017, 8, 32237–32257. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Frota, R.; Turna, B.; Barros, R.; Gill, I.S. Comparison of radical prostatectomy techniques: Open, laparoscopic and robotic assisted. Int. Braz. J. Urol. 2008, 34, 259–269. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Walz, J.; Attard, G.; Bjartell, A.; Blanchard, P.; Castro, E.; Compérat, E.; Emmett, L.; Fanti, S.; Fonteyne, V.; Foulon, S.; et al. Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2026, 37, 453–469. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Eastham, J.A.; Barocas, D.A.; Chu, C.E.; Morgans, A.K.; Rodrigues, G.; Kirkby, E.; Pak, L.J.; Patel, S. Clinically localized prostate cancer: AUA/ASTRO guideline amendment (2026). J. Urol. 2026, 216, 2–11. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Pal, R.P.; Koupparis, A.J. Expanding the indications of robotic surgery in urology: A systematic review of the literature. Arab J. Urol. 2018, 16, 270–284. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Abdelhakim, M.A.; Abdelwahab, M. Robot-assisted radical prostatectomy with the Versius surgical platform: An objective criticism and a guide for an optimal surgical setup. Arab J. Urol. 2025, 23, 152–159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Dibitetto, F.; Castellucci, R.; Russo, P.; Marino, F.; Gavi, F.; Ragonese, M.; Foschi, N.; Nigro, D.; Akhundov, A.; Defidio, L.; et al. Extraperitoneal robot-assisted radical prostatectomy by the da Vinci and Versius System: First comparative analysis. Minerva Urol. Nephrol. 2024, 76, 570–577. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Carbonara, U.; Srinath, M.; Crocerossa, F.; Ferro, M.; Cantiello, F.; Lucarelli, G.; Porpiglia, F.; Battaglia, M.; Ditonno, P.; Autorino, R. Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: An evidence-based analysis of comparative outcomes. World J. Urol. 2021, 39, 3721–3732. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Kim, D.K.; Moon, Y.J.; Chung, D.Y.; Jung, H.D.; Jeon, S.H.; Kang, S.H.; Paick, S.; Lee, J.Y. Comparison of robot-assisted, laparoscopic, and open radical prostatectomy outcomes: A systematic review and network meta-analysis from KSER update series. Medicina 2025, 61, 61. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Brime Menendez, R.; García Rojo, E.; Hevia Palacios, V.; Feltes Ochoa, J.A.; Justo Quintas, J.; Lista Mateos, F.; Fraile, A.; Manfredi, C.; Belli, S.; Bozzini, G.; et al. Da Vinci vs. Hugo RAS for robot-assisted radical prostatectomy: A prospective comparative single-center study. World J. Urol. 2024, 42, 336. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Fernández-Conejo, G.; Subiela Henríquez, J.D.; Tagalos Muñoz, A.; González Álvarez, C.; Fernández Mardomingo, A.; Sanz Mayayo, E.; Díez Nicolás, V.; García Barreras, S.; Gómez Dos Santos, V.; Rodríguez-Patrón, R.; et al. Standardizing radical prostatectomy with the Versius robotic system: Technical setup and early institutional experience. J. Robot. Surg. 2025, 19, 470. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. De Maria, M.; Meneghetti, I.; Mosillo, L.; Collins, J.W.; Catalano, C. Versius robotic surgical system: Case series of 18 robot-assisted radical prostatectomies. BJU Int. 2024, 133, 197–205. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Reddy, K.; Gharde, P.; Tayade, H.; Patil, M.; Reddy, L.S.; Surya, D. Advancements in robotic surgery: A comprehensive overview of current utilizations and upcoming frontiers. Cureus 2023, 15, e50415. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Hughes, T.; Rai, B.; Madaan, S.; Chedgy, E.; Somani, B. The Availability, Cost, Limitations, Learning Curve and Future of Robotic Systems in Urology and Prostate Cancer Surgery. J. Clin. Med. 2023, 12, 2268. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Haig, F.; Medeiros, A.C.B.; Chitty, K.; Slack, M. Usability assessment of Versius, a new robot-assisted surgical device for use in minimal access surgery. BMJ Surg. Interv. Health Technol. 2020, 2, e000028. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Thomas, B.C.; Slack, M.; Hussain, M.; Barber, N.; Pradhan, A.; Dinneen, E.; Stewart, G.D. Preclinical evaluation of the Versius surgical system, a new robot-assisted surgical device for use in minimal access renal and prostate surgery. Eur. Urol. Focus 2021, 7, 444–452. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Soumpasis, I.; Nashef, S.; Dunning, J.; Moran, P.; Slack, M. Safe implementation of surgical innovation: A prospective registry of the Versius robotic surgical system. BMJ Surg. Interv. Health Technol. 2023, 5, e000144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. Available online: https://www.wma.net/policies-post/wma-declaration-of-helsinki/ (accessed on 28 April 2026).
  20. Cornford, P.; Tilki, D.; van den Bergh, R.C.N.; Briers, E.; Eberli, D.; De Meerleer, G.; De Santis, M.; Gillessen, S.; Henry, A.M.; van Leenders, G.J.L.H.; et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer; European Association of Urology: Arnhem, The Netherlands, 2024; Available online: https://d56bochluxqnz.cloudfront.net/documents/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024.pdf (accessed on 28 April 2026).
  21. Evidencio. Novel Briganti Nomogram: Predicting the Risk of Lymph Node Involvement in Prostate Cancer Patients. Available online: https://www.evidencio.com/models/show/917 (accessed on 28 April 2026).
  22. Murphy, D.G.; Challacombe, B.J.; Costello, A.J. Outcomes after robot-assisted laparoscopic radical prostatectomy. Asian J. Androl. 2009, 11, 94–99. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Mazzone, E.; Mistretta, F.A.; Knipper, S.; Tian, Z.; Larcher, A.; Widmer, H.; Zorn, K.; Capitanio, U.; Graefen, M.; Montorsi, F.; et al. Contemporary national assessment of robot-assisted surgery rates and total hospital charges for major surgical uro-oncological procedures in the United States. J. Endourol. 2019, 33, 438–447. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Gaia, G.; Sighinolfi, M.C.; Afonina, M.; Terzoni, S.; Iannuzzi, V.; Felline, M.; Morandi, A.; Alboni, C.; Marca, A.L.; Ceretti, A.P.; et al. Versius surgical system: Tips and tricks for OR setting and port placement for pelvic surgery, our experience in a multi-robotic referral centre. Langenbecks Arch. Surg. 2025, 410, 252. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Połom, W.; Matuszewski, M. Initial experience of the Versius robotic system in robot-assisted radical prostatectomy: A study of 58 cases. Cent. Eur. J. Urol. 2024, 77, 30–36. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Reitano, G.; Tumminello, A.; Ghaffar, U.; Saggionetto, G.; Taverna, A.; Mangiacavallo, F.; Ahmed, M.E.; Basourakos, S.P.; Carletti, F.; Minardi, D.; et al. Perioperative, oncological, and functional outcomes of new multiport robotic platforms in urology: A systematic review and meta-analysis. Eur. Urol. Open Sci. 2025, 74, 44–70. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Meneghetti, I.; Dibitetto, F.; Mariotti, A.; Morganti, R.; Collins, J.; Pacetti, P.; Corsini, A.; Mosillo, L.; Belli, S.; Boni, R.; et al. Preliminary multicenter experience with the Versius robotic surgical system for radical prostatectomy: Oncological outcomes with a minimum 18-month of follow-up. Int. J. Med. Robot. Comput. Assist. Surg. 2026, 22, e70144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Yossepowitch, O.; Briganti, A.; Eastham, J.A.; Epstein, J.; Graefen, M.; Montironi, R.; Touijer, K. Positive surgical margins after radical prostatectomy: A systematic review and contemporary update. Eur. Urol. 2014, 65, 303–313. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Abdelhakim, M.; Morsy, S.; Abdelghany, M.; Fouad, A.; Abdelwahab, M. Outcomes and efficacy of robotic-assisted radical prostatectomy using the CMR Versius platform: A prospective study on 118 patients with 1-year follow-up. Int. Urol. Nephrol. 2025, 57, 2081–2087. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Gandi, C.; Marino, F.; Totaro, A.; Scarciglia, E.; Bellavia, F.; Bientinesi, R.; Gavi, F.; Russo, P.; Ragonese, M.; Palermo, G.; et al. Perioperative outcomes of robotic radical prostatectomy with Hugo™ RAS versus daVinci surgical platform: Propensity score-matched comparative analysis. J. Clin. Med. 2024, 13, 3157. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Balestrazzi, E.; Paciotti, M.; Piro, A.; Piramide, F.; Bravi, C.A.; Peraire Lores, M.; Mottaran, A.; Sorce, G.; Ticonosco, M.; Frego, N.; et al. Comparative analysis of robot-assisted simple prostatectomy: The HUGO™ RAS system versus the DaVinci® Xi system. Prostate Cancer Prostatic Dis. 2024, 27, 122–128. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.